Opthea (OPT) Announces Executive Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
Opthea Announces Executive Leadership Changes and Senior Hires
September 5, 2024 6:00 AM EDTDaniel Geffken appointed Chief Financial Officer ad interim
Mike Campbell appointed Chief Commercial Officer
Three senior leaders appointed for Biometrics, Clinical Operations and Market Access
MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, Opthea, the Company), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market... More
